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j Abstract Mitochondrial neuro-
gastrointestinal encephalomyopa-
thy (MNGIE) is a rare autosomal
recessive disorder in which a
nuclear mutation of the thymidine
phosphorylase (TP) gene causes
mitochondrial genomic dysfunc-
tion. Patients suffer from gastro-
intestinal dysmotility, cachexia,
ptosis, external ophthalmoparesis,
myopathy and polyneuropathy.
Magnetic resonance imaging
(MRI) shows leukoencephalopa-
thy. We describe clinical, genetic
and neuroradiological features of
three brothers affected with
MNGIE. Clinical examination,
laboratory analyses, MRI and
magnetic resonance spectroscopy
(MRS) of the brain, and genetic
analysis have been performed in
all six members of the family with
the three patients with MNGIE.
Two of them are monozygous
twins. They all suffered from gas-
trointestinal dysmotility, cachexia,
ophthalmoplegia, muscular atro-
phies, and polyneuropathy. Uri-
nary thymidine was elevated in the
patients related to the severity of
clinical disease, and urinary thy-
midine (normally not detectable)
was also found in a heterozygous
carrier. Brain MRI showed leu-
koencephalopathy in all patients;
however, their cognitive function-
ing was normal. Brain MRS
demonstrated reduced
N-acetylaspartate and choline in
severely affected areas. MRI of
heterozygous carriers was normal.
A new mutation (T92N) in the TP
gene was identified. Urinary thy-
midine is for the first time
reported to be detectable in a
heterozygous carrier. MRS find-
ings indicate loss of neurons,
axons, and glial cells in patients
with MNGIE, but not in
heterozygous carriers.
j Key words mitochondrial
neurogastrointestinal encephal-
omyopathy MNGIE Æ
thymidine phosphorylase Æ
magnetic resonance spectroscopy
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Introduction
Mitochondrial neuro-gastro-intestinal encephalomy-
opathy (MNGIE; Mendelian Inheritance in Man
number 603041, Genome Database accession number
9835128) is a rare autosomal recessive disorder. To
date, fewer than 100 verified [1–33] patients have been
published. Its cause is a mutation in the gene for
thymidine phosphorylase (TP) [34, 35] on chromo-
some 22q13.32-qter that leads to deletions in and a
depletion of mitochondrial DNA. MNGIE is thus a
mitochondriopathy caused by a nuclear genomic de-
fect. Clinical hallmarks are disturbed gastrointestinal
motility with intestinal pseudoobstruction, cachexia,
ptosis, external ophthalmoplegia, and polyneuropa-
thy. The brain MRI shows leukodystrophy, and
mitochondrial dysfunction can be found in laboratory
tests. Life expectancy is reduced and death occurs as
a result of cachexia and intestinal complications. A
specific therapy is not known however, one patient
has recently successfully undergone stem cell trans-
plantation [35a].
We describe a family with 4 children, in whom
three brothers are affected. Two affected brothers and
the healthy sister are triplets. Moreover, the two
triplet brothers are monozygous twins. The sister and
the parents are healthy and have normal weight and
muscles. There is no known consanguinity of the
parents.
Patients and Methods
j Patient reports
Patient 1
The 22 year-old male index patient was referred after several epi-
sodes of non mechanical intestinal obstruction of unknown cause.
Pregnancy, birth and psychomotor development were normal. At
age 3, he suffered from intestinal obstruction, and during child-
hood and adolescence he had recurrent abdominal pain, frequent
diarrhoea and occasional vomiting. At age 22, laparoscopy per-
formed because of acute abdominal pain showed inflamed intes-
tines and peritonitis without obstruction. A few months later,
nonmechanical ileus required resection of a part of the small
intestine. Numerous diverticula were found, and the muscularis
propria near the large blood vessels was lacking. Histology showed
foamy cells in the intestinal wall. Gastroscopy was normal. Steatosis
hepatis was noted on abdominal ultrasonography. The patient
worked full time in an office after an apprenticeship in business
administration. At age 22, limitations in physical activity started. At
age 23, a bilateral ptosis developed. He complained of flatulence
and erectile dysfunction. The clinical exam showed scoliosis and
marked muscular atrophy, mainly of the shoulder and pelvic girdle.
Muscle strength was mildly reduced. Body weight was 50 kg and
height was 180 cm (BMI 15.4 kg/m2). Loud borborygmi were heard.
Extraocular movements were severely limited horizontally and
upwards. Pupillary reaction to convergence was delayed and lim-
ited. Sensation in the hands was normal except for mildly impaired
stereognosis. Perception of vibration, temperature and touch was
clearly reduced in both feet. Tendon reflexes were absent except for
symmetrically very weak biceps reflexes and knee jerks. Romberg’s
test was positive and tandem gait was not possible without cor-
rection steps.
Nerve conduction studies: Conduction velocity of the right
peroneal nerve was slowed in the popliteal fossa segment (25 m/s);
the compound muscle potential (CMP)of the anterior tibial muscle
was normal, but no CMP of the extensor digitorum brevis muscle
could be elicited. Motor nerve conduction of the right ulnar nerve
was slowed (above elbow 33 m/s, elbow-wrist 31 m/s) and motor
latency to the abductor digiti V muscle was prolonged (4.6 ms).
The amplitudes of the CMP were normal. No conduction blocks
were noted. Sensory-antidromic potentials of the right ulnar nerve,
sensory-orthodromic potentials of the left sural nerve, and F-waves
were absent. Qualitative and quantitative electromyographies of the
right tibialis anterior and the right interosseus dorsalis I muscle
were normal. In summary, electrophysiology confirmed axonal and
demyelinating sensorimotor neuropathy.
MRI of the brain showed large confluent hyperintense signal
changes on T2-weighted and FLAIR images indicating leukoence-
phalopathy, predominantely in the periventricular areas and the
pons.
The electrocardiogram showed sinus rhythm and incomplete
right bundle branch block.
Genetic testing of the mitochondrial genome showed no dele-
tions of mtDNA in lymphocytes and skeletal muscle. Depletion of
mtDNA was not assessed. Lactate (3.1 mmol/l, normal 0.63–2.44)
and serum liver enzymes were elevated (aspartate aminotransferase
50 U/l, normal 10–41; alanine aminotransferase 86 U/l, normal 5–41;
gamma-glutamyltransferase 103 U/l, normal 11–64). Extensive lab-
oratory blood testing showed no additional abnormalities. Cere-
brospinal fluid analysis showed one mononuclear cell and elevated
values for lactate (4.6 mmol/l, normal 1.2–2.1) and protein (2.71 g/l,
normal < 0.44). The clinical and laboratory findings suggested
MNGIE. The diagnosis was confirmed by a thymidine phosphorylase
(TP) assay that did not show any activity in leucocytes.
At age 24 non mechanical ileus recurred and additional parts of
the small bowel were resected. Both sensory and motor signs of
neuropathy progressed after initiation of total parenteral nutrition.
Thorough laboratory testing did not identify a nutritive cause, but
fluctuating signs suggested an inflammatory cause. However,
intravenous immunoglobulins (a total of 300 g given in six cycles)
did not improve neuropathic signs, as found by others [36].
Patient 2
The older twin brother was seen at age 20. He was asymptomatic
and his previous medical history unremarkable. He indicated
occasional moderate borborygmi when he had an empty stomach.
His weight had been constant at 52 kg, his height was 174 cm (BMI
17.2 kg/m2). He was working full time at an office and experienced
no limitations in gymnastics or basketball. Muscles of the shoulders
and pelvic girdle were slightly atrophic and strength mildly re-
duced. Tendon reflexes of the arms were absent, but Achilles ten-
don reflexes were normal. Sensation of both hands was normal.
Pallaesthesia of both feet was slightly impaired. There was exotr-
opia. Corrected visual acuity was 0.6 on the left and 0.9 on the right.
Upward gaze was limited and there was a fluctuating ptosis on the
left. Cardiac auscultation suggested mitral valve prolapse.
Patient 3
The younger twin brother weighed only 1750 g at birth. He was
examined at age 20 years when his weight was 49 kg and the height
174 cm (BMI 16.2 kg/m2). He occasionally suffered from diarrhoea
and vomiting. For some months flatulence, and for years
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borborygmi had been present. At age 13, surgery for strabismus
was performed. He was working full time as a gardener and did not
engage in any sports. There were cachexia and marked atrophies of
the back, shoulder and thigh muscles and moderate proximal
weakness of the arms and mild weakness of the legs. Corrected
vision was 0.6 on the right and 0.8 on the left, and there was
exotropia. Upward gaze was limited to less than 20 and pupillary
reaction to convergence was delayed and impaired. Tendon reflexes
of the arms were absent and weak in the legs. Tactile sensation was
normal. Perception of vibration of the legs was slightly diminished.
The patient was unsteady when standing with closed eyes. Blood
pressure was 105/65 mm Hg. There were a systolic heart murmur
and loud borborygmi.
j Genetic testing
Genomic DNA was extracted from circulating blood white cells
using a Qiagen kit (Qiagen, Valencia, California, USA) according to
manufacturer’s instruction and amplified by PCR using the enzyme
Taq Plus from Stratagene (La Jolla, California, USA). Primers were
designed to amplify the open reading frame and exon-intron
boundaries into 4 fragments, which encompassed exons 2–3; 4; 5–6;
and 7–10, respectively. The amplified products were purified using
the QIAquick PCR purification kit protocol and cycle sequenced
using the Big Dye Terminator sequencing kit (Perkin-Elmer, Foster
City, California, USA) on an ABI 3100 genetic analyser (Applied
Biosystems, Foster City, California, USA). The study was approved
by the local ethics committee. Written informed consent was ob-
tained from all participants.
j Magnetic resonance imaging and spectroscopy
MRI was performed on a 1.5T Sonata (Siemens, Erlangen, Ger-
many) in the four siblings and their parents. Axial T1 weighted spin
echo (T1w)-, T2 (T2w)-, and proton density weighted (PDw) fast
spin echo, diffusion weighted images and coronal FLAIR images
were obtained. In additon, magnetic resonance spectroscopy (MRS)
was performed. In the affected brothers sagittal T2w scans and axial
T1w scans after intravenous (i.v.) administration of 0.1 mmol/kg
body weight gadolinium-DTPA (Magnevist, Schering, Berlin, Ger-
many) were also obtained.
MRS was performed before contrast administration using point
resolved spectroscopy (PRESS) technique (TR 1500 msec, TE
135 msec, 192 averages). Two voxels, each sized 1.5 · 1.5 · 1.5 cm3,
were placed in the white matter of the right hemisphere, one in the
centrum semiovale and the other in the paratrigonal region. For each
region a non-water suppressed signal spectrum was also recorded to
perform eddy current correction. Spectroscopic data were quantified
using a prior knowledge based fitting algorithm (TDFDFIT) [37].
Peak areas of water, N-acetylaspartate (NAA), choline (Cho), crea-
tine/phosphocreatine (Cr) and lactate (Lac) were assessed and
metabolite ratios of NAA/Cr and Cho/Cr calculated. For group
comparison mean values of the three affected brothers were
compared to that of their healthy relatives (Table 1).
Follow-up MRI scans of the index patient were compared with a
MRI examination performed 11 months earlier on a 1.5 T Signa
scanner (GE Medical system, Milwaukee, USA) including a coronal
FLAIR sequence, axial PDw, T2w and T1w images before and after
i.v. Gd-DTPA.
j Urine analysis
Thymidine was assessed by liquid chromatography in spontaneous
urine samples of all family members with a technique adapted from
Simmonds et al. [38]. Urine samples were frozen at )20 C after
collection and later analysed by chromatography. Thymidine levels
were assessed in relation to creatinine in the urine samples.
Results
j Genetic testing
The three affected members of the family were
homozygous for a new mutation in exon 3 at
g.2182C > A (genomic). This caused a ACC to AAC
codon change and a T92N aminoacid substitution.
The healthy parents and sister were heterozygous C/A
for the same mutation. 100 chromosomes of controls
did not show this mutation (Fig. 1).
j MRI and spectroscopy findings
The MR scans of the three affected brothers showed
widespread and nearly symmetrical signal changes,
hyperintense on T2w and hypointense on T1w images
(Fig. 2). In the index patient, signal changes were
Table 1 Magnetic resonance spectroscopy
Paratrigonal white matter Centrum semiovale
Water Cho Cr NAA NAA/Cr Cho/Cr Water Cho Cr NAA NAA/Cr Cho/Cr
Patient 1 6.98 16.75 11.17 21.36 1.91 1.5 5.72 13.84 10.07 23.51 2.34 1.38
Patient 2 4.84 18.63 16.36 26.72 1.63 1.14 3.45 17.49 16.22 33.67 2.08 1.08
Patient 3 4.17 14.97 11.43 23.37 2.08 1.31 3.05 16.29 12.08 29.55 2.45 1.35
Mean 5.33 16.79 12.98 23.93 1.87 1.32 4.07 15.87 12.79 28.91 2.29 1.27
SD 1.20 1.83 2.93 2.68 0.23 0.18 1.44 1.86 3.14 5.11 0.19 0.17
Sister 3.4 17.75 12.95 29.82 2.30 1.37 2.56 15.33 13.62 30.90 2.27 1.13
Mother 3.00 26.49 17.31 33.15 1.92 1.53 2.75 21.64 15.35 35.75 2.33 1.41
Father 2.88 25.40 18.55 32.72 1.76 1.37 2.68 21.52 13.29 31.41 2.36 1.38
Mean 3.09 23.31 16.27 31.89 1.99 1.42 2.66 19.50 14.09 32.69 2.32 1.31
SD 0.27 4.76 2.94 1.81 0.28 0.09 0.10 3.61 1.11 2.67 0.05 0.15
Peak intensities are given as institutional units. NAA = N-acetylaspartate, Cr = creatine and phosphocreatine, Cho = choline and choline containing compounds
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pronounced in the periventricular white matter and
also involved the corpus callosum, pons, internal
capsule, thalamus and putamen. Arcuate fibres and
the cerebellum were spared. There was no brain
atrophy, no blood-brain-barrier breakdown, and no
acute diffusion disturbance. The follow-up MRI in the
index patient did not show progression of the signal
changes after 11 months. MRI of the two less affected
brothers showed patchy periventricular hyperinten-
sities on T2w images, but less pronounced than in the
index patient. The white matter of the temporal lobes,
brain stem, arcuate fibres, corpus callosum, and
internal capsules was spared. There was no atrophy
and no enhancement after gadolinium administration.
Diffusion weighed images were normal. Cerebral MRI
of the parents and the sister were normal.
MRS (Fig. 3) did not show any lactate-peak. Areas
of T2w hyperintense white matter showed increased
water content that was highest in the index patient
(Table 1). In the paratrigonal region group compari-
son of the three affected brothers with their three
healthy relatives showed a reduction of NAA (mean
patients 23.9 ± 2.68 vs. mean controls 31.9 ± 1.81),
Cho (mean patients 16.8 ± 1.83 vs. mean controls
23.3 ± 4.76), and Cr (mean patients 13.0 ± 2.93 vs.
mean controls 16.3 ± 2.94). Water signal was clearly
increased in the patients (mean patients 5.33 ± 1.12
vs. mean controls 3.09 + 0.27). Owing to the few
measurements, no statistical analyses have been per-
formed.
Metabolite changes in the centrum semiovale were
less pronounced. Metabolites were most reduced in
the index patient, who also showed extensive T2w
signal changes in this location as compared with his
brothers, in whom these areas were much less affected
on conventional MRI. No differences for the calcu-
lated ratios (NAA/Cr and Cho/Cr) were observed in
the centrum semiovale.
j Urine analysis
Thymidine was not detectable in the mother and the
healthy sister. Thymidine was 86.3 lmol/mmol cre-
atinine in the index patient and 25.5 and 20.9 lmol/
mmol creatinine in his two affected brothers. Thy-
Patient
Parent
TP SEQUENCE
Control
COMPARISON OF TP EXON 3 SEQUENCES
Fig. 1 Electropherograms of the DNA sequence analysis of the thymidine phosphorylase (TP) exon 3 showing the C2182A mutation (arrow) in the homozygotic
(patient) and heterozygotic state (father) and a healthy control
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midine was 1.97 lmol/mmol creatinine in the father.
Creatinine was normal in all samples.
Discussion
The first clinical description of MNGIE dates back to
1976 [1] as ‘‘congenital oculosceletal myopathy with
abnormal muscle and liver mitochondria’’. In 1994,
Hirano et al. [14] coined the name of autosomal
recessive MNGIE for this mitochondrial disorder
with a nuclear genetic defect. Other previously used
acronyms and names for syndromes that probably
correspond to MNGIE were POLIP [5] (polyneur-
opathy, ophthalmoplegia, leukoencephalopathy, and
intestinal pseudo-obstruction), OGMID [12] (oculo-
gastrointestinal muscular dystrophy), and MEPOP
[39] (mitochondrial encephalomyopathy with sen-
sorimotor polyneuropathy, ophthalmoplegia, and
pseudo-obstruction). MNGIE is caused by a muta-
tion in the nuclear gene for TP, gene locus 22q13.32-
qter [34, 35]. We describe a new mutation in exon 3
at g.2182C > A with a ACC to AAC codon change
that leads to a T92N amino acid substitution. Syn-
onyms for TP are platelet-derived endothelial cell
growth factor (PDECGF), endothelial cell growth
factor 1 (ECGF1), and gliostatin. Many reports have
indicated a role of PDECGF in angiogenesis, cell
trophism and tumour growth, and inhibition of glial
cell proliferation and neurotrophic actions. However,
Fig. 2 Axial T2 weighted images of the index
patient at the level of A) pons, B) basal ganglia and
C) centrum semiovale showing focal hyperintensities
in the brain stem and confluent hyperintensities of
the cerebral white matter sparing U-fibres. Much less
pronounced white matter changes are present in the
paratrigonal region in the younger brother (D). There
is no atrophy in either patient
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loss of function in MNGIE is not associated with
altered angiogenesis or neoplasms. TP catalyses the
reversible phosphorolysis of thymidine and phos-
phate to thymine and 2-deoxy-D-ribose-1-phosphate.
Mutations lead to loss of function of TP in patients
[35] and to reduced activity in heterozygote carriers
[40], resulting in more than 60-fold increased plasma
levels of thymidine in MNGIE [40] and also in an
increase of deoxyuridine [41]. This leads to a mito-
chondrial nucleotide pool imbalance with elevated
levels of deoxythymidine triphosphate [42], which, in
turn, may cause dysfunction of mitochondrial DNA
replication, repair, or both [43] resulting in altera-
tions of mitochondrial DNA [44].
Ten years after Hirano et al. [14] had outlined
clinical diagnostic criteria for MNGIE, biochemical
assays for its diagnosis were created [45] (plasma
levels of thymidine and deoxyuracil, and TP activity
in buffy coat). Elevated urinary thymidine [40] and
deoxyuridine, thymine, and uracil [46] have been
reported recently in MNGIE and may be used for
diagnostic purposes. Our results indicate that uri-
nary thymidine may be not only a diagnostic mea-
sure, but also correlate with the severity of the
clinical disease. Normally, thymidine is not detected
in urine. Therefore, detectable urinary thymidine in
the patients’ father is likely to relate to his hetero-
zygous state. Heterozygous relatives have reduced
TP activity, but undetectable thymidine serum levels
(< 0.05 lM). Detectable urinary thymidine in a
heterozygous person has, yet to our knowledge not
been described.
The clinical manifestations of the few known
MNGIE patients have been reviewed in detail [8, 20,
43]. Frequent findings in MNGIE ( > 70% of all cases
in the series of Hirano et al. [43]) that we observed
in one or more of our patients were: cachexia, intes-
tinal pseudo-obstruction, borborygmi, abdominal
pain, diarrhoea, early satiety, abdominal cramps,
nausea, vomiting, ptosis, ophthalmoparesis, poly-
neuropathy, and areflexia. Further findings in our
index patient that have been described in MNGIE
previously are: diverticulosis of the small intestine,
hepatopathy, lactic acidosis, elevated CSF protein, and
abnormal nerve conduction tests. Cognitive impair-
ment is typically absent. Leukoencephalopathy was
present in all of our patients. Incomplete right bundle
branch block – as found in our index patient – has
previously been noted [43]. Except for three recently
reported patients with late-onset MNGIE [32], all
previously reported patients had died by the age of
58 years, and the average life expectancy of deceased
patients was 37 years. The delay until diagnosis is
long, in the average over 10 years, as in our index
patient. A causal therapy does not exist, and proki-
netic agents are not efficient. Total parenteral nutri-
tion may delay cachexia. One reported patient
responded well to celiac plexus neurolysis [8]. Stem
cell transplantation has been successful in one patient
so for and may be used in further patients [35a].
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Fig. 3 Point resolved spectroscopy (PRESS)
(repetition time 1500 ms, echo time 135 ms)
localized in the paratrigonal white matter of the
index patient (A and B) and his healthy mother
(C and D). T2-weighted MRI (B and D) and
corresponding MR spectra (A and C). MR spectra
(A and C) and fit are shown on the upper trace, the
residuum after fit is shown on the lower trace. No
lactate was found at 1.33 ppm. Levels of all
metabolites were diminished in the index patient.
NAA = N-acetylaspartate, Cr = creatine and
phosphocreatine, Cho = choline and choline
containing compounds
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Brain spectroscopy has according to our knowl-
edge not been detailed in typical cases of MNGIE. The
higher age of the heterozygous control group may
have influenced metabolite concentrations. NAA de-
creases with age in grey matter which corresponds to
volume loss of the cortex. However, there was no
brain atrophy on MRI, and NAA and Cho in white
matter are not age dependent [47, 48]. The changes
observed in our patients are therefore probably dis-
ease related. Areas of T2w hyperintensities correlated
with increased water content. Despite the lack of
volume loss of brain tissue in conventional MRI, MRS
revealed a reduction of NAA and choline in the se-
verely affected areas. This might indicate loss of
neurons, axons, as well as glial cells [49, 50]. The lack
of a reduction in the less affected white matter indi-
cates that MRS is not able to detect metabolite
changes earlier than conventional MRI detects white
matter abnormalities indicative of leukoencephalop-
athy. Because all three main metabolites (NAA, Cr
and Cho) are reduced, ratios (NAA/Cr and Cho/Cr)
do not differ between patients and controls. The
reduction was strongest in the index patient sug-
gesting a correlation of the clinical course, the extent
of leukoencephalopathy and NAA and choline de-
crease. Therefore, these values may be useful in follow
up examinations. The lack of a lactate peak corre-
sponds to the slowly progressive course of the disease
and suggests intact aerobic glycolysis.
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